uniQure Q3 net loss $47.9M; DSMB recommends resuming higher-dose AMT-130 enrollment

uniQure N.V.

2022-Q3 EPS reported -$2.86 revenue$3,738,000

Net loss $47.9M ($1.02/share) vs $36.5M ($0.79) in Q3 2021; revenue $1.4M down from $2.0M.
Cash $440.3M as of Sep 30, 2022; expected to fund operations into H1 2025.
DSMB recommends resuming higher-dose AMT-130 enrollment in European Phase Ib/II after SUSARs resolved.
BLA for etranacogene dezaparvovec under FDA priority review; EMA issued GMP certificate.
IND-enabling studies initiated for AMT-260 (epilepsy) and AMT-191 (Fabry); submissions expected 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

uniQure N.V. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 2, 2022, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and highlighting company progress.

View on SEC.gov

Browse all earnings releases →

uniQure N.V. filing history →

Source: SEC EDGAR

accession 0001104659-22-113966

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.